HBM Holdings H1 revenue rises amid mid-to-late clinical program progress
HBM Holdings says its H1 revenue rose as progress continues on mid-to-late clinical stage programs.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.